Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beacon-BTC: Nanvuranlat in Advanced Biliary Tract Cancer
NCT07265674Phase 3Recruiting
- Sponsor
- J-Pharma
- Start
- May 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of JPH203 in biliary tract cancer (BTC), sponsored by J-Pharma. Started May 2026; status: recruiting.
02
Drugs
JPH203
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07265674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07265674.